In a new job - March 1, 2022
LEO Pharma appoints a new CEO
The company has announced the appointment of Christophe Bourdon as new Chief Executive Officer, effective April 1, 2022. Christophe Bourdon joins from Orphazyme A/S where he has held the position as CEO since April 2021, following global leadership roles in both Amgen and Alexion. Read more: LEO Pharma introduces a new operating model and organizational […]
Pharma Business - January 26, 2022
LEO Pharma introduces a new operating model and organizational structure
The next phase in the company’s strategy towards 2023 is expected to affect around 1,000 positions in the global organization over the next two years. In 2020, LEO Pharma unveiled its strategy towards 2030. The first phase of this process – including the introduction of a new capital and governance structure – was recently completed. The next phase, announced now, […]
In a new job - January 7, 2022
LEO Pharma’s CEO leaves the company
The Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company. LEO Pharma has recently completed the first phase of its strategic transformation process – including the development of a new capital and governance structure. The next phase […]
Acquisition - December 6, 2021
Aqilion acquires anti-inflammatory program from LEO Pharma
Aqilion has strengthened its pipeline with an innovative development program in the field of chronic inflammation. With this acquisition, Aqilion is taking over all rights to the program, now under the name Regulus, from LEO Pharma. The project is ready for clinical trials and Aqilion plans to begin clinical development in 2022. Aqilion will make an […]
Pharma Business - July 7, 2021
LEO Pharma receives European approval of Adtralza
The European Commission has approved Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The European approval makes Adtralza the first high affinity, fully human monoclonal antibody approved to specifically bind to and inhibit the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms, […]
In a new job - December 29, 2020
LEO Pharma appoints EVP Global Research and Development
LEO Pharma has announced that Joerg Moeller will join its Global Leadership Team as Executive Vice President, Global Research and Development. Moeller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee. “Joerg Moeller’s experience will help us to significantly foster our innovative […]
